US Hemophilia Factor Brands by Company and Type

MANUFACTURER	RECOMBINANT			PLASMA-DERIVED		
	FVIII	FIX	Inhibitor	FVIII	FIX	Inhibitor
Medexus Pharmaceuticals[1]		Ixinity®				
Bayer	Kogenate®FS *Kovaltry®* *Jivi®*					
CSL Behring	*Afstyla®*	*Idelvion®*		Humate-P®	Mononine®	
Grifols				Alphanate®	AlphaNine®S/D Profilnine®	
HEMA Biologics, LLC[2]			Sevenfact®			
Kedrion[3]				Koate®-DVI		
Novo Nordisk	Novoeight® *Esperoct®*	*Rebinyn®*	NovoSeven®RT			
Octapharma	Nuwiq®			wilate®		
Pfizer	Xyntha®	BeneFIX®				
Sanofi Genzyme	*Eloctate®*	*Alprolix®*				
Takeda	Advate *Adynovate* Recombinate	Rixubis		Hemofil M	Proplex-T	FEIBA VH

Italicized brand names indicate extended half-life products. Because there is no consensus on what constitutes an extended half-life product, check the package insert (PI) carefully. The half-life of a product may also vary widely from patient to patient, and may vary widely with age (younger=shorter half-life; older=longer half-life). Have a pharmacokinetic (PK) test to determine your individual factor half-life, and discuss with your HTC hematologist which product best meets your treatment needs.

Recombinate is a first-generation recombinant product. Kogenate FS is a second-generation product. Advate, Adynovate, Afstyla, Alprolix, BeneFIX, Esperoct, Idelvion, Ixinity, Jivi, Kovaltry, Novoeight, Rebinyn, Rixubis, Vonvendi and Xyntha are third-generation products. Nuwiq and Eloctate are fourth generation products (made using human cell lines).

1. Medexus Pharmaceuticals acquired the rights to Ixinity in February 2020.

2. HEMA Biologics distributes Sevenfact in the US for LFB S.A. (Laboratoire français du Fractionnement et des Biotechnologies, South America), which is the manufacturer. Sevenfact is produced by rabbits which have been genetically engineered to secrete human factor VIIa in their milk.

3. Kedrion distributes Koate-DVI in the US for Grifols, which is the manufacturer.

Small-Molecule Hemophilia Therapies

Manufacturer	Product	Type	Indication
Genentech	Hemlibra®	Bispecific antibody (not a factor product). Administered subcutaneously weekly, biweekly or monthly.	Routine prophylaxis in adults and children with hemophilia A, with or without factor VIII inhibitors. Use of more than 100 U/kg total of aPCC (FEIBA®) for treating breakthrough bleeds increases risk of blood clots. Consult your healthcare provider before using FEIBA.